Fig. 1From: Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancerCONSORT diagram. Scheme showing an HLA-A-status double-blind, biologically randomized phase II study of three therapeutic epitope peptides combined with gemcitabine as a first-line therapy for advanced pancreatic cancer (VENUS-PC study)Back to article page